Neuraly is a clinical-stage biotechnology company with a mission to develop groundbreaking drugs that can greatly enhance and extend the lives of individuals afflicted by neurological conditions like Parkinson's disease (PD), Alzheimer's disease (AD), and other neurodegenerative disorders. By leveraging their expertise in glia biology and understanding the role of neuroinflammation and neuroprotection, Neuraly is working to create a diverse portfolio of risk-diversified products for PD and AD. Neuraly is a subsidiary of D&D Pharmatech, a global biotech company dedicated to revolutionizing medicine through the establishment of disease-specific subsidiary companies guided by esteemed medical research faculty and biotech professionals.

Their lead asset, NLY01, is an innovative, long-acting, microglia-targeted GLP-1R agonist that effectively tackles microglia/astrocytes-induced neuroinflammation. In preclinical models of PD and AD, NLY01 has demonstrated strong therapeutic efficacy. Currently in Phase 2 for early Parkinson's and Alzheimer's patients, Neuraly is also conducting IND-enabling studies for additional small molecule candidates with distinct yet complementary mechanisms for PD and AD.

Neuraly believes that NLY01 has the potential to be a disease-modifying therapy, slowing the progression of neurodegenerative diseases. With the aim to address the lack of treatments that can reverse or halt neurodegeneration, Neuraly is at the forefront of advancing scientific discoveries in neurology. For more information on Neuraly and their parent company, D&D Pharmatech, please visit their website at http://www.

ddpharmatech. com/